Goal and Learning Outcomes

Upon successful completion of this educational activity, you should be better prepared to:

  • Characterize the clinical relevance of common genetic mutations involved in the etiology of ALS
  • Discuss the mechanism of action and clinical trial results of antisense oligonucleotides that target SOD1 mutations
  • Assess patient eligibility for ongoing lung cancer clinical trials and treatment regimens under investigation


Jinsy A. Andrews, MD, MSc, FAAN

Director of Neuromuscular Clinical Trials
Columbia University Irving Medical Center
New York, NY
Associate Professor of Neurology
Department of Neurology
Columbia University
New York, NY

Terry D. Heiman-Patterson, MD

Professor of Neurology
Director MDA ALS Center of Hope
Department of Neurology
Lewis Katz School of Medicine at Temple University
Philadelphia, PA

Accreditation Information

This course is being provided by a Relias LLC strategic partner.  Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.